Geisinger research: Antimalarial drug prevents diabetes in arthritis patientsOctober 29, 2008Study presented at ACR meeting DANVILLE, PA - The use of an antimalarial medication may prevent the onset of diabetes in patients with rheumatoid arthritis, new Geisinger research shows. Researchers examined the records of 2,093 Geisinger patients who received treatment for rheumatoid arthritis from 2000 to 2008. The study looked at, among other things, use of the medication hydroxychloroquine (HCQ) and the development of new cases of diabetes in these patients. HCQ was developed to treat malaria but it has also been used to treat rheumatoid arthritis and other autoimmune diseases. In patients with rheumatoid arthritis, use of HCQ was associated with a 53 percent reduction in the development of new cases of diabetes, the study found. "Given the relative safety and low cost of this generic drug, HCQ may be useful in preventing diabetes in other high risk groups," said lead study investigator and Geisinger rheumatologist Androniki Bili, MD, MPH. Researchers don't know how exactly HCQ prevents diabetes onset but it's suspected that HCQ improves glucose tolerance. Dr. Bili presented the study's findings Monday at the American College of Rheumatology Annual Scientific Meeting in San Francisco. About 23.6 million Americans have diabetes, while 1.3 million have rheumatoid arthritis. People with rheumatoid arthritis are at increased risk for diabetes due to more sedentary lifestyle, chronic inflammation and use of steroid medications that can cause weight gain. "We should revisit HCQ in the treatment of rheumatoid arthritis because, in addition to its disease-modifying properties, it might prevent the development of diabetes in this high risk group," Dr. Bili said. Geisinger Health System |
|||||||||||||||||||||
| Related Rheumatoid Arthritis Current Events and Rheumatoid Arthritis News Articles Researchers find new way to attack inflammation in Graves' eye disease A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Pain thresholds linked to inflammation and sleep problems in arthritis patients Despite recent advances in anti-inflammatory therapy, many rheumatoid arthritis (RA) patients continue to suffer from pain. New therapy for vasculitis will help patients avoid infertility and cancer Researchers have identified that Rituxan, a drug previously approved for the treatment of non-Hodgkin's B cell lymphoma and rheumatoid arthritis, can treat severe ANCA-associated vasculitis as effectively as cyclophosphamide, the current standard therapy. Strategy for mismatched stem cell transplants triggers protection against graft-vs.-host disease A new technique being tested in stem-cell transplants from imperfectly matched donors has revealed a striking, unforeseen response that can suppress graft-versus-host disease, a common and dangerous complication of mismatched transplants, report scientists from Dana-Farber Cancer Institute. Grains and lamb offer new sources of omega-3 CSIRO research on grains and lamb aimed at developing new dietary sources of long-chain omega-3 oils will be presented at the World Congress on Oils and Fats in Sydney this week. Visionary concept earns La Jolla Institute scientist prestigious NIH Pioneer Award A scientist at the La Jolla Institute for Allergy & Immunology has received one of the National Institutes of Health (NIH)'s top awards -- the 2009 NIH Director's Pioneer Award. Experimental approach may reverse rheumatoid arthritis and osteoporosis Researchers have identified a mechanism that may keep a well known signaling molecule from eroding bone and inflaming joints, according to an early study published online today in the Journal of Clinical Investigation. Promising new target emerges for autoimmune diseases University of Michigan scientists say they have uncovered a fundamentally new mechanism that holds in check aggressive immune cells that can attack the body's own cells. New 'biofactories' produce rare healing substances in the endangered Devil's claw plant Deep in Africa's Kalahari Desert lies the "Devil's claw," a plant that may hold the key to effective treatments for arthritis, tendonitis and other illnesses that affect millions each year. Abnormal Brain Circuits May Prevent Movement Disorder Most people who carry a genetic mutation for a movement disorder called dystonia will never develop symptoms, a phenomenon that has puzzled scientists since the first genetic mutation was identified in the 1990's. More Rheumatoid Arthritis Current Events and Rheumatoid Arthritis News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||